Barclays PLC Acquires 61,317 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI)

Barclays PLC lifted its holdings in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) by 180.8% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 95,232 shares of the company’s stock after purchasing an additional 61,317 shares during the period. Barclays PLC owned about 0.12% of Trevi Therapeutics worth $319,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. BNP Paribas Financial Markets grew its holdings in Trevi Therapeutics by 130.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 11,930 shares of the company’s stock worth $40,000 after acquiring an additional 6,764 shares during the last quarter. Intech Investment Management LLC bought a new stake in Trevi Therapeutics in the 3rd quarter worth $63,000. Hsbc Holdings PLC bought a new stake in Trevi Therapeutics in the 2nd quarter worth $61,000. SG Americas Securities LLC bought a new stake in Trevi Therapeutics in the 3rd quarter worth $78,000. Finally, The Manufacturers Life Insurance Company lifted its position in shares of Trevi Therapeutics by 87.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 24,524 shares of the company’s stock worth $73,000 after purchasing an additional 11,450 shares during the period. Institutional investors own 95.76% of the company’s stock.

Wall Street Analysts Forecast Growth

TRVI has been the subject of several research analyst reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $8.00 target price on shares of Trevi Therapeutics in a research report on Thursday, December 12th. D. Boral Capital reaffirmed a “buy” rating and issued a $21.00 target price on shares of Trevi Therapeutics in a research report on Wednesday, January 8th. HC Wainwright raised their target price on shares of Trevi Therapeutics from $6.00 to $7.50 and gave the stock a “buy” rating in a research report on Thursday, December 12th. Finally, B. Riley reissued a “buy” rating and set a $6.00 price target on shares of Trevi Therapeutics in a research report on Monday, October 7th. Eight equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $9.31.

Trevi Therapeutics Stock Performance

NASDAQ:TRVI opened at $3.76 on Monday. The firm has a market cap of $289.03 million, a P/E ratio of -8.55 and a beta of 0.87. Trevi Therapeutics, Inc. has a fifty-two week low of $1.27 and a fifty-two week high of $4.68. The firm has a 50-day simple moving average of $3.50 and a two-hundred day simple moving average of $3.18.

Trevi Therapeutics (NASDAQ:TRVI) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). During the same quarter last year, the company posted ($0.08) EPS. On average, equities research analysts predict that Trevi Therapeutics, Inc. will post -0.49 EPS for the current year.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.